Liver and Multiorgan Transplant Unit, Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy.
Ann Surg Oncol. 2011 Jun;18(6):1630-7. doi: 10.1245/s10434-010-1463-8. Epub 2010 Dec 7.
With substantial improvements in perioperative care and surgical technique, both mortality and morbidity after liver resection have progressively decreased; however, long-term prognosis is greatly affected by tumor recurrence, which represents the most frequent cause of death. The aim of this study is to analyze the outcome after hepatic resection in the present clinical scenario, where great improvements in diagnostic techniques, surveillance schedules, in other active treatments will potentially have a positive impact on survival.
Data from 300 consecutive hepatic resections performed on cirrhotic patients in a tertiary-care referral hospital from 1997 and 2008 were reviewed, and survival was calculated for the two periods considered. The first group of patients underwent hepatectomy between 1997 and 2002 (n = 126) and the second group of patients between 2003 and 2008 (n = 174).
In the more recent period, tumor selection criteria for resectability included more patients with multinodular tumors so that solitary tumors decreased from 89.7 to 78.7% (P = 0.019); however, the tumor, node, metastasis (TNM) system stage remained unaffected. The 5-year recurrence rate remained similar (67.4 vs. 65.8%; P = 0.836). Despite these features, the 5-year patient survival increased from 52.6 to 65.8% (P = 0.023). This end result was related to a larger proportion of patients with tumor recurrence undergoing repeat resection or salvage transplantation that increased from 22.2 to 36.9% (P = 0.039).
The increased survival is most likely the result of more stringent follow-up as well as increased accuracy in detecting recurrence at earlier stages, and consequently of more chances for potential cure when treating recurrent tumor.
随着围手术期护理和外科技术的显著进步,肝切除术后的死亡率和发病率都逐渐降低;然而,肿瘤复发极大地影响了长期预后,这是死亡的最常见原因。本研究旨在分析目前临床情况下肝切除术后的结果,其中诊断技术、监测方案和其他积极治疗的进步可能对生存产生积极影响。
回顾了 1997 年至 2008 年在一家三级转诊医院对 300 例肝硬化患者进行的连续肝切除术的数据,并计算了考虑的两个时期的生存率。第一组患者在 1997 年至 2002 年期间接受肝切除术(n=126),第二组患者在 2003 年至 2008 年期间接受肝切除术(n=174)。
在最近的时期,可切除性的肿瘤选择标准包括更多的多结节肿瘤患者,因此单发肿瘤从 89.7%降至 78.7%(P=0.019);然而,肿瘤、淋巴结、转移(TNM)系统分期保持不变。5 年复发率保持相似(67.4%与 65.8%;P=0.836)。尽管存在这些特征,5 年患者生存率仍从 52.6%增加到 65.8%(P=0.023)。这一最终结果与更多接受重复切除或挽救性移植的肿瘤复发患者相关,这一比例从 22.2%增加到 36.9%(P=0.039)。
生存率的提高可能是由于更严格的随访以及更早阶段检测复发的准确性提高,从而在治疗复发性肿瘤时获得更多潜在治愈的机会。